Research ExplorerPublicationsContinuous centrifugal microfluidics (CCM) isolates heteroge...

Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation

Standard

Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation. / Woo, Hyeong Jung; Kim, Seung-Hoon; Kang, Hyo Jung; Lee, Soo-Hwan; Lee, Seung Joon; Kim, Jong Man; Gurel, Ogan; Kim, Soo Yeol; Roh, Hye Ran; Lee, Jungmin; Park, Yeonsoo; Shin, Hyun Young; Shin, Yong-Il; Lee, Sun Min; Oh, So Yeon; Kim, Young Zoon; Chae, Jung-Il; Lee, Seoyoung; Hong, Min Hee; Cho, Byoung Chul; Lee, Eun Sook; Pantel, Klaus; Kim, Hye Ryun; Kim, Minseok S.

In: THERANOSTICS, Vol. 12, No. 8, 2022, p. 3676-3689.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Woo, HJ, Kim, S-H, Kang, HJ, Lee, S-H, Lee, SJ, Kim, JM, Gurel, O, Kim, SY, Roh, HR, Lee, J, Park, Y, Shin, HY, Shin, Y-I, Lee, SM, Oh, SY, Kim, YZ, Chae, J-I, Lee, S, Hong, MH, Cho, BC, Lee, ES, Pantel, K, Kim, HR & Kim, MS 2022, 'Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation', THERANOSTICS, vol. 12, no. 8, pp. 3676-3689. https://doi.org/10.7150/thno.72511

APA

Woo, H. J., Kim, S-H., Kang, H. J., Lee, S-H., Lee, S. J., Kim, J. M., Gurel, O., Kim, S. Y., Roh, H. R., Lee, J., Park, Y., Shin, H. Y., Shin, Y-I., Lee, S. M., Oh, S. Y., Kim, Y. Z., Chae, J-I., Lee, S., Hong, M. H., ... Kim, M. S. (2022). Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation. THERANOSTICS, 12(8), 3676-3689. https://doi.org/10.7150/thno.72511

Vancouver

Woo HJ, Kim S-H, Kang HJ, Lee S-H, Lee SJ, Kim JM et al. Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation. THERANOSTICS. 2022;12(8):3676-3689. https://doi.org/10.7150/thno.72511

Bibtex

@article{693ffc674e4f4f26899bc64e29879f89,
title = "Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation",
abstract = "Understanding cancer heterogeneity is essential to finding diverse genetic mutations in metastatic cancers. Thus, it is critical to isolate all types of CTCs to identify accurate cancer information from patients. Moreover, full automation robustly capturing the full spectrum of CTCs is an urgent need for CTC diagnosis to be routine clinical practice. Methods: Here we report the full capture of heterogeneous CTC populations using fully automated, negative depletion-based continuous centrifugal microfluidics (CCM). Results: The CCM system demonstrated high performance (recovery rates exceeding 90% and WBC depletion rate of 99.9%) across a wide range of phenotypes (EpCAM(+), EpCAM(-), small-, large-sized, and cluster) and cancers (lung, breast, and bladder). Applied in 30 lung adenocarcinoma patients harboring epidermal growth factor receptor (EGFR) mutations, the system isolated diverse phenotypes of CTCs in marker expression and size, implying the importance of unbiased isolation. Genetic analyses of intra-patient samples comparing cell-free DNA with CCM-isolated CTCs yielded perfect concordance, and CTC enumeration using our technique was correlated with clinical progression as well as response to EGFR inhibitors. Conclusion: Our system also introduces technical advances which assure rapid, reliable, and reproducible results, thus enabling a more comprehensive application of robust CTC analysis in clinical practice.",
keywords = "Automation, Cell Line, Tumor, Cell Separation/methods, Epithelial Cell Adhesion Molecule/genetics, ErbB Receptors/genetics, Humans, Microfluidics/methods, Neoplastic Cells, Circulating/metabolism",
author = "Woo, {Hyeong Jung} and Seung-Hoon Kim and Kang, {Hyo Jung} and Soo-Hwan Lee and Lee, {Seung Joon} and Kim, {Jong Man} and Ogan Gurel and Kim, {Soo Yeol} and Roh, {Hye Ran} and Jungmin Lee and Yeonsoo Park and Shin, {Hyun Young} and Yong-Il Shin and Lee, {Sun Min} and Oh, {So Yeon} and Kim, {Young Zoon} and Jung-Il Chae and Seoyoung Lee and Hong, {Min Hee} and Cho, {Byoung Chul} and Lee, {Eun Sook} and Klaus Pantel and Kim, {Hye Ryun} and Kim, {Minseok S}",
note = "{\textcopyright} The author(s).",
year = "2022",
doi = "10.7150/thno.72511",
language = "English",
volume = "12",
pages = "3676--3689",
journal = "THERANOSTICS",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "8",

}

RIS

TY - JOUR

T1 - Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation

AU - Woo, Hyeong Jung

AU - Kim, Seung-Hoon

AU - Kang, Hyo Jung

AU - Lee, Soo-Hwan

AU - Lee, Seung Joon

AU - Kim, Jong Man

AU - Gurel, Ogan

AU - Kim, Soo Yeol

AU - Roh, Hye Ran

AU - Lee, Jungmin

AU - Park, Yeonsoo

AU - Shin, Hyun Young

AU - Shin, Yong-Il

AU - Lee, Sun Min

AU - Oh, So Yeon

AU - Kim, Young Zoon

AU - Chae, Jung-Il

AU - Lee, Seoyoung

AU - Hong, Min Hee

AU - Cho, Byoung Chul

AU - Lee, Eun Sook

AU - Pantel, Klaus

AU - Kim, Hye Ryun

AU - Kim, Minseok S

N1 - © The author(s).

PY - 2022

Y1 - 2022

N2 - Understanding cancer heterogeneity is essential to finding diverse genetic mutations in metastatic cancers. Thus, it is critical to isolate all types of CTCs to identify accurate cancer information from patients. Moreover, full automation robustly capturing the full spectrum of CTCs is an urgent need for CTC diagnosis to be routine clinical practice. Methods: Here we report the full capture of heterogeneous CTC populations using fully automated, negative depletion-based continuous centrifugal microfluidics (CCM). Results: The CCM system demonstrated high performance (recovery rates exceeding 90% and WBC depletion rate of 99.9%) across a wide range of phenotypes (EpCAM(+), EpCAM(-), small-, large-sized, and cluster) and cancers (lung, breast, and bladder). Applied in 30 lung adenocarcinoma patients harboring epidermal growth factor receptor (EGFR) mutations, the system isolated diverse phenotypes of CTCs in marker expression and size, implying the importance of unbiased isolation. Genetic analyses of intra-patient samples comparing cell-free DNA with CCM-isolated CTCs yielded perfect concordance, and CTC enumeration using our technique was correlated with clinical progression as well as response to EGFR inhibitors. Conclusion: Our system also introduces technical advances which assure rapid, reliable, and reproducible results, thus enabling a more comprehensive application of robust CTC analysis in clinical practice.

AB - Understanding cancer heterogeneity is essential to finding diverse genetic mutations in metastatic cancers. Thus, it is critical to isolate all types of CTCs to identify accurate cancer information from patients. Moreover, full automation robustly capturing the full spectrum of CTCs is an urgent need for CTC diagnosis to be routine clinical practice. Methods: Here we report the full capture of heterogeneous CTC populations using fully automated, negative depletion-based continuous centrifugal microfluidics (CCM). Results: The CCM system demonstrated high performance (recovery rates exceeding 90% and WBC depletion rate of 99.9%) across a wide range of phenotypes (EpCAM(+), EpCAM(-), small-, large-sized, and cluster) and cancers (lung, breast, and bladder). Applied in 30 lung adenocarcinoma patients harboring epidermal growth factor receptor (EGFR) mutations, the system isolated diverse phenotypes of CTCs in marker expression and size, implying the importance of unbiased isolation. Genetic analyses of intra-patient samples comparing cell-free DNA with CCM-isolated CTCs yielded perfect concordance, and CTC enumeration using our technique was correlated with clinical progression as well as response to EGFR inhibitors. Conclusion: Our system also introduces technical advances which assure rapid, reliable, and reproducible results, thus enabling a more comprehensive application of robust CTC analysis in clinical practice.

KW - Automation

KW - Cell Line, Tumor

KW - Cell Separation/methods

KW - Epithelial Cell Adhesion Molecule/genetics

KW - ErbB Receptors/genetics

KW - Humans

KW - Microfluidics/methods

KW - Neoplastic Cells, Circulating/metabolism

U2 - 10.7150/thno.72511

DO - 10.7150/thno.72511

M3 - SCORING: Journal article

C2 - 35664056

VL - 12

SP - 3676

EP - 3689

JO - THERANOSTICS

JF - THERANOSTICS

SN - 1838-7640

IS - 8

ER -